What is BenchSci?
Founded in 2015 and headquartered in Toronto, BenchSci operates at the intersection of artificial intelligence and pharmaceutical research. By leveraging machine learning to parse millions of scientific papers, the company provides researchers with actionable insights that significantly reduce the time and cost associated with preclinical drug development. As the industry shifts toward data-centric R&D, BenchSci has positioned itself as an essential infrastructure provider for global biopharma organizations, effectively digitizing the laboratory workflow to enhance reproducibility and scientific output.
How much funding has BenchSci raised?
BenchSci has raised a total of $163M across 4 funding rounds:
Series A
$8M
Series B
$22M
Series C
$63M
Series D
$70M
Series A (2018): $8M, investors not publicly disclosed
Series B (2020): $22M led by Fidelity
Series C (2022): $63M supported by Inovia and Technology Crossover Ventures
Series D (2023): $70M featuring Technology Crossover Ventures, Generation Investment Management, and Inovia
Key Investors in BenchSci
Technology Crossover Ventures
Technology Crossover Ventures is a Menlo Park-based firm established in 1995 that specializes in growth-stage investments, including acquisitions and recapitalizations for technology-driven enterprises.
Generation Investment Management
Generation Investment Management focuses on mobilizing capital to foster sustainable economic systems, prioritizing long-term value creation through strategic advocacy and investment in impactful technologies.
Inovia
iNovia Capital is a full-stack venture firm based in Montreal that partners with founders to build enduring global technology companies by emphasizing a people-first investment philosophy.
What's next for BenchSci?
With the infusion of this latest capital, BenchSci is well-positioned to scale its enterprise-level operations and expand its AI capabilities into broader therapeutic areas. The strategic focus will likely center on deepening market penetration within top-tier pharmaceutical firms while refining its predictive analytics engine. By maintaining a strong balance sheet, the company is prepared to navigate the complexities of the biotech landscape, ensuring that its software remains the gold standard for antibody selection and experimental optimization in an increasingly competitive global market.
See full BenchSci company page
